X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
medical and health sciences (100) 100
medicin och hälsovetenskap (100) 100
clinical medicine (78) 78
klinisk medicin (78) 78
humans (65) 65
female (55) 55
male (54) 54
middle aged (54) 54
reumatologi och inflammation (52) 52
rheumatology and autoimmunity (52) 52
index medicus (48) 48
rheumatology (48) 48
adult (43) 43
aged (40) 40
risk factors (38) 38
rheumatoid arthritis (37) 37
medicine (30) 30
medicin (29) 29
sweden - epidemiology (28) 28
adolescent (25) 25
antirheumatic agents - therapeutic use (19) 19
arthritis, rheumatoid - drug therapy (19) 19
risk (19) 19
arthritis, rheumatoid - complications (17) 17
cancer (17) 17
cohort studies (17) 17
registries (17) 17
tumor necrosis factor-alpha - antagonists & inhibitors (17) 17
research (16) 16
arthritis, rheumatoid - epidemiology (15) 15
lymphoma (14) 14
lymphomas (14) 14
disease (13) 13
rheumatoid-arthritis (13) 13
young adult (13) 13
case-control studies (12) 12
lymphoma - epidemiology (12) 12
methotrexate (12) 12
oncology (12) 12
aged, 80 and over (11) 11
arthritis (11) 11
care and treatment (11) 11
epidemiology (11) 11
incidence (11) 11
non-hodgkins-lymphoma (11) 11
cancer and oncology (10) 10
cancer och onkologi (10) 10
dosage and administration (10) 10
patients (10) 10
antirheumatic agents - adverse effects (9) 9
association (9) 9
follow-up studies (9) 9
lymphoma - etiology (9) 9
register (9) 9
sweden (9) 9
autoimmunity (8) 8
infliximab (8) 8
metaanalysis (8) 8
population (8) 8
survival (8) 8
tumor necrosis factor-tnf (8) 8
abridged index medicus (7) 7
classification (7) 7
complications and side effects (7) 7
dmards (7) 7
epidemiologic methods (7) 7
epstein-barr-virus (7) 7
etanercept (7) 7
health aspects (7) 7
health risk assessment (7) 7
immunosuppression (7) 7
mortality (7) 7
prognosis (7) 7
retrospective studies (7) 7
systemic-lupus-erythematosus (7) 7
tnf inhibitors (7) 7
treatment outcome (7) 7
united-states (7) 7
adalimumab (6) 6
anti-tnf (6) 6
antibodies, monoclonal - therapeutic use (6) 6
antirheumatic agents (6) 6
arthritis, rheumatoid - immunology (6) 6
autoimmune (6) 6
child (6) 6
drug therapy (6) 6
inflammation (6) 6
lymphoma - pathology (6) 6
lymphoma, non-hodgkin - epidemiology (6) 6
non-hodgkin-lymphoma (6) 6
primary sjogrens-syndrome (6) 6
proportional hazards models (6) 6
prospective studies (6) 6
safety (6) 6
studies (6) 6
sweden/epidemiology (6) 6
therapy (6) 6
tumor necrosis factor (6) 6
1506 (5) 5
b-cell lymphoma (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
International Journal of Cancer, ISSN 0020-7136, 03/2013, Volume 132, Issue 6, pp. 1429 - 1438
Journal Article
Journal Article
Seminars in Cancer Biology, ISSN 1044-579X, 2014, Volume 24, pp. 61 - 70
For decades, it has been known that patients with certain autoimmune and inflammatory disorders, such as rheumatoid arthritis (RA) and primary Sjögren's... 
Genetic events | Chronic inflammation | Antigen stimulation | Autoimmune disease | Lymphoma | Risk factors
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 06/2015, Volume 74, Issue 6, pp. 1212 - 1217
Objective To estimate the risk of tuberculosis (TB) in patients with rheumatoid arthritis (RA) both with and without exposure to biological therapy and to... 
SWEDEN | REGISTER | Rheumatoid Arthritis | SERIOUS INFECTION | Anti-TNF | MONOCLONAL-ANTIBODY | NECROSIS-FACTOR ANTAGONISTS | RHEUMATOLOGY | FACTOR THERAPY | Tuberculosis | Treatment | DISEASES | BRITISH-SOCIETY | AGENTS | INFLIXIMAB | Tuberculosis - epidemiology | Antibodies, Monoclonal, Humanized - therapeutic use | Humans | Middle Aged | Risk Factors | Arthritis, Rheumatoid - epidemiology | Proportional Hazards Models | Immunoglobulin G - therapeutic use | Antibodies, Monoclonal - therapeutic use | Male | Sweden - epidemiology | Case-Control Studies | Receptors, Tumor Necrosis Factor - therapeutic use | Etanercept | Infliximab | Arthritis, Rheumatoid - drug therapy | Adult | Female | Aged | Adalimumab | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Antirheumatic Agents - therapeutic use | Biological Products - therapeutic use | Cohort Studies | Complications and side effects | Care and treatment | Usage | Biological products | Rheumatoid arthritis | Health aspects | Risk factors | Drugs | Disease | Laboratories | Bias | Rheumatology | Personal identification numbers | Estimates | Studies | Education | Immunotherapy | Quality | Rheumatism | Population | TNF inhibitors | Tumor necrosis factor-TNF | Chronic obstructive pulmonary disease | Basic Medicine | Immunologi inom det medicinska området | Medical and Health Sciences | Medicin och hälsovetenskap | Immunology in the medical area | Medicinska och farmaceutiska grundvetenskaper
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 06/2015, Volume 74, Issue 6, pp. 970 - 978
Objective To assess the effect of comedication with conventional synthetic disease modifying antirheumatic drugs (csDMARDs) on retention to tumour necrosis... 
RHEUMATOID-ARTHRITIS | EFFICACY | Anti-TNF | METHOTREXATE | RHEUMATOLOGY | PSORIATIC-ARTHRITIS | Spondyloarthritis | SOCIETY CLASSIFICATION CRITERIA | Ankylosing Spondylitis | DMARDs (synthetic) | IMMUNOGENICITY | TREATMENT RESPONSE | NECROSIS FACTOR THERAPY | INFLIXIMAB | CONTINUATION | Sulfasalazine - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Prospective Studies | Humans | Middle Aged | Spondylitis, Ankylosing - drug therapy | Proportional Hazards Models | Immunoglobulin G - therapeutic use | Antibodies, Monoclonal - therapeutic use | Male | Spondylarthritis - drug therapy | Treatment Outcome | Methotrexate - therapeutic use | Receptors, Tumor Necrosis Factor - therapeutic use | Etanercept | Infliximab | Survival Analysis | Adult | Female | Adalimumab | Drug Therapy, Combination | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Antirheumatic Agents - therapeutic use | Care and treatment | Antirheumatic agents | Tumor necrosis factor inhibitors | Spondyloarthropathies | Dosage and administration | Research | Ankylosing spondylitis | Risk factors | Studies | Inflammatory bowel disease | Immunoglobulins | Psoriasis | Disease | Socioeconomic factors | TNF inhibitors | Tumor necrosis factor-TNF | Arthritis | Patients | Rheumatology and Autoimmunity | Clinical Medicine | Medical and Health Sciences | Medicin och hälsovetenskap | Reumatologi och inflammation | Klinisk medicin
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 10/2007, Volume 66, Issue 10, pp. 1339 - 1344
Journal Article
Seminars in Cancer Biology, ISSN 1044-579X, 2013, Volume 24, pp. 61 - 70
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 12/2017, Volume 76, Issue 12, pp. 2025 - 2030
BackgroundLymphomas comprise a heterogeneous group of malignant diseases with highly variable prognosis. Rheumatoid arthritis (RA) is associated with a twofold... 
DMARDs(biologic) | epidemiology | rheumatoid arthritis | anti-TNF | SURVIVAL | AUTOIMMUNE | MALIGNANT-LYMPHOMAS | SERIOUS INFECTION | SAFETY | METHOTREXATE | RISK | DISORDERS | RHEUMATOLOGY | NECROSIS FACTOR THERAPY | Lymphoma - epidemiology | Humans | Middle Aged | Risk Factors | Europe - epidemiology | Male | Lymphoma, Non-Hodgkin - epidemiology | Arthritis, Rheumatoid - complications | Lymphoma, B-Cell - epidemiology | Lymphoma - etiology | Arthritis, Rheumatoid - drug therapy | Lymphoma, T-Cell - etiology | Female | Lymphoma - pathology | Registries | Lymphoma, B-Cell - etiology | Lymphoma, T-Cell - epidemiology | Antirheumatic Agents - therapeutic use | Lymphoma, Non-Hodgkin - etiology | Tumor Necrosis Factors - antagonists & inhibitors | Complications and side effects | Care and treatment | Antirheumatic agents | Rheumatoid arthritis | Dosage and administration | Non-Hodgkin's lymphomas | Hodgkin's disease | Risk factors | Chronic lymphatic leukemia | Disease | Leukemia | Rheumatology | Rheumatic diseases | Lymphocytes T | Non-Hodgkin's lymphoma | Patients | Cancer therapies | Lymphocytes B | Tumor necrosis factor | Collaboration | Population | TNF inhibitors | Tumor necrosis factor-TNF | Lymphomas | Health risk assessment | T-cell lymphoma | Tumors | B-cell lymphoma | Life Sciences | Clinical and Epidemiological Research | 2311 | 655 | 1506 | Rheumatology and Autoimmunity | Clinical Medicine | Medical and Health Sciences | Medicin och hälsovetenskap | Reumatologi och inflammation | Klinisk medicin
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 11/2007, Volume 66, Issue 11, pp. 1491 - 1496
Journal Article